AOTI's Groundbreaking Therapy Set to Transform Healthcare for Diabetic Patients

AOTI Inc. is on the cusp of a significant breakthrough in diabetic foot ulcer treatment, following a proposed Local Coverage Determination (LCD) by the Centers for Medicare & Medicaid Services (CMS). This proposed policy endorses the use of topical oxygen therapy for diabetic foot ulcers that have not healed after four weeks of standard care, marking a vital step toward broader access for millions of patients.

Positive Developments for Patient Care

Dr. Mike Griffiths, CEO of AOTI, discussed the implications of this proposal during an interview. If finalized after a 45-day comment period, the LCD is expected to establish Medicare coverage for AOTI's innovative TWO2® intermittent topical wound oxygen therapy. This coverage would dramatically increase patient access across the United States, potentially benefiting approximately 69 million Medicare beneficiaries suffering from chronic diabetic foot ulcers.

Impact on the Healthcare Landscape

The anticipated policy change not only signifies improved treatment access but also aligns with efforts to accelerate reimbursement across Medicaid, commercial insurers, and managed care organizations. This could lead to a substantial reduction in reimbursement risks for providers. With AOTI holding a 75% market share in topical oxygen therapy, its TWO2® platform stands out as the only intermittent topical oxygen wound therapy available on the market today.

Transformative Outcomes Supported by Research

Clinical studies have highlighted the effectiveness of AOTI's therapy, showcasing improved long-term healing outcomes compared to traditional treatments. With an established commercial presence across 26 states, AOTI is well-positioned to take advantage of this expansion initiative. The estimated serviceable market for AOTI currently represents a $400 million revenue opportunity, and the broader CMS-driven reimbursement could elevate this to an impressive $26 billion in the long run.

This proposed evolution in healthcare policy has the potential to affect not just individual patients but the entire landscape of diabetic ulcer treatments, fostering a future where effective therapies are accessible to those in need.